Oscotec Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oscotec Inc. - overview
Established
1988
Location
Seongnam, -, South Korea
Primary Industry
Biotechnology
About
Oscotec Inc. , based in South Korea, specializes in innovative biotechnology solutions, particularly in advanced drug delivery systems and therapeutic products designed to improve treatment efficacy and patient outcomes. Founded in 1988 and headquartered in Seongnam, South Korea, Oscotec Inc. develops therapeutic solutions focused on drug delivery systems.
The company has undergone strategic shifts to enhance its product offerings, including its recent PIPE funding round. James Kim and Taeyoung Yoon are the current CEOs. In December 2019, the company raised KRW 22 billion in a PIPE transaction led by E&Investment, which represents the entirety of its total amount raised. Oscotec develops advanced solutions in the biotechnology sector, with a focus on drug delivery systems and therapeutic products.
Their core offerings include formulation technologies that enhance pharmaceutical compounds' efficacy and bioavailability, addressing complex drug delivery challenges. Their clientele includes pharmaceutical firms and research institutions in North America and Europe, with end users being healthcare professionals and patients who benefit from improved treatment methods. In the most recent year, Oscotec reported a revenue of KRW 13,812,431 and an EBITDA of KRW 2,147,931. The company generates revenue through partnerships with pharmaceutical companies and research entities, structured around collaborative development agreements and licensing arrangements for their proprietary technologies.
Oscotec plans to utilize the KRW 22 billion raised in December 2019 to accelerate clinical trials for its Phase 2a treatment for rheumatoid arthritis and its Phase 1a treatment for acute myelogenous leukemia. The company aims to expand its market presence in North America and Europe, enhancing its product range by introducing new formulations in the coming years.
Current Investors
E&Investment
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.oscotec.com
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Oscotec Inc. - timeline of key events
Oscotec Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 25,966,280,458 | 24,755,850,116 | 21,858,819,377 | 17,110,321,233 | 18,335,817,610 | 3,553,891,396 | 3,908,490,780 | 18,702,671,511 | 4,368,519,899 | 43,470,793,384 | 3,902,734,752 | 5,062,376,493 | - | - | - |
| % Revenue Growth (YoY) | - | (4.7%) | (11.7%) | (21.7%) | 7.2% | (80.6%) | 10.0% | 378.5% | (76.6%) | 895.1% | (91.0%) | 29.7% | - | - | - |
| EBITDA (USD) | 968,574,252 | 2,129,229,399 | (475,555,822) | (344,288,377) | 1,199,389,582 | (1,292,573,818) | (1,263,494,064) | 6,485,539,783 | (19,452,689,958) | 2,468,975,090 | (26,552,299,426) | (26,872,395,258) | - | - | - |
| Operating Income (USD) | 639,150,106 | (773,446,332) | (885,162,654) | (756,272,635) | 685,599,342 | (1,739,508,487) | (1,637,183,469) | 6,177,595,385 | (19,856,234,674) | 1,580,436,682 | (28,096,765,516) | (28,638,371,344) | - | - | - |
| Operating Margin | 2.5% | (3.1%) | (4.0%) | (4.4%) | 3.7% | (48.9%) | (41.9%) | 33.0% | (454.5%) | 3.6% | (719.9%) | (565.7%) | - | - | - |
| % EBITDA Margin | 3.7% | 8.6% | (2.2%) | (2.0%) | 6.5% | (36.4%) | (32.3%) | 34.7% | (445.3%) | 5.7% | (680.4%) | (530.8%) | - | - | - |
| NET Income (USD) | (2,423,710,688) | (14,383,012,613) | (3,937,256,333) | (2,056,869,595) | 363,431,083 | (4,400,635,213) | (4,275,864,880) | 4,278,281,889 | (24,963,194,556) | (2,046,709,557) | (28,589,754,575) | (27,773,705,664) | - | - | - |
| % Net Margin | (9.3%) | (58.1%) | (18.0%) | (12.0%) | 2.0% | (123.8%) | (109.4%) | 22.9% | (571.4%) | (4.7%) | (732.6%) | (548.6%) | - | - | - |
Oscotec Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Oscotec Inc. | - |
Displaying 1 - 1 of 1
Oscotec Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.